sermorelin peptide vs bpc 157 What to know: the 4 peptides FDA just cleared ipamorelin vs bpc 157 A

Half-life data reinforces the contrast

The barrier will still be an investigational new drug application in an FDA designated disease indication (of which for many of these peptide use cases, there isn't one)

Mild swelling at injection site A small bump or slight puffiness where you injected is normalit's just the fluid sitting under the skin before absorption

If you have been managing a chronic soft tissue issue, GI inflammation that standard approaches have not resolved, or post-surgical recovery that is progressing slower than expected, a BPC-157 consultation at our Doral clinic starts with a full clinical intake, not a generic protocol handed off without context